LIQUIDIA CORPORATION (LQDA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 189.30M USD | Liabilities, Current |
| Cash and equivalents | 284.18M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 108.58M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 36.18M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $189.30M | $284.18M | (m) | $108.58M | $36.18M | (m) |
| 2026-03-31 | (m) | $149.74M | $222.79M | (m) | $74.16M | $28.51M | (m) |
| 2025-12-31 | (m) | $135.77M | $190.68M | (m) | $54.09M | $23.80M | (m) |
| 2025-09-30 | (m) | $102.94M | $157.50M | (m) | $35.96M | $24.53M | (m) |
| 2025-06-30 | (m) | $78.41M | $173.42M | (m) | $9.97M | $6.44M | (m) |
| 2025-03-31 | (m) | $60.52M | $169.76M | (m) | $1.25M | $1.35M | (m) |
| 2024-12-31 | (m) | $41.78M | $176.48M | (m) | $2.72M | $241.00K | (m) |
| 2024-09-30 | (m) | $33.84M | $204.37M | (m) | $4.20M | $38.00K | (m) |
| 2024-06-30 | (m) | $24.22M | $133.09M | (m) | $3.25M | (m) | (m) |
| 2024-03-31 | (m) | $21.93M | $157.86M | (m) | $2.57M | (m) | (m) |
| 2023-12-31 | (m) | $18.55M | $83.68M | (m) | $4.06M | (m) | (m) |
| 2023-09-30 | (m) | $12.16M | $76.22M | (m) | $3.34M | (m) | (m) |
| 2023-06-30 | (m) | $19.50M | $88.20M | (m) | $4.09M | (m) | (m) |
| 2023-03-31 | (m) | $6.82M | $94.41M | (m) | $4.13M | (m) | (m) |
| 2022-12-31 | (m) | $8.80M | $93.28M | (m) | $5.02M | (m) | (m) |
| 2022-09-30 | (m) | $7.46M | $98.32M | (m) | $3.14M | (m) | (m) |
| 2022-06-30 | (m) | $6.84M | $103.84M | (m) | $3.75M | (m) | (m) |
| 2022-03-31 | (m) | $7.98M | $57.79M | (m) | $3.29M | (m) | (m) |
| 2021-12-31 | (m) | $7.33M | $57.49M | (m) | $2.99M | (m) | (m) |
| 2021-09-30 | (m) | $7.06M | $64.05M | (m) | $3.05M | (m) | (m) |
| 2021-06-30 | (m) | $6.97M | $67.89M | (m) | $2.99M | (m) | (m) |
| 2021-03-31 | (m) | $7.88M | $53.64M | (m) | $627.60K | (m) | (m) |
| 2020-12-31 | (m) | $11.74M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $16.87M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |